In the United States, truvada, combined with more abundant sexual practices, is indicated for HIV PrEP to reduce the risk of sexual seropositivity in people who are vulnerable to HIV and who weigh ≥35 kg. Descovy, in combination with other antiretrovirals, is authorized to treat HIV infection in patients weighing ≥25 kg and is not authorized worldwide for PrEP. The use of Descovy for an indication of HIV-PrEP is in the trial and was not considered safe or effective. FOSTER CITY, Calif.-(BUSINESS WIRE)-May 9, 2019– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Truvada will donate Truvada to PrEP® (Emtricitabine 200 mg and 300 mg of tenofovir disoproxil tablets) to the U.S. Centers for Disease Control and Prevention (CDC) to support national efforts to prevent HIV and end the epidemic. . . .